We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMersana Therapeutics Inc

Mersana Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-02-05T21:14:15.807617Z
Market Cap
291.22M

Momentum Score

…

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.80
Low
9.62
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
38.30M
Revenue Per Share
0.32
Gross Profit TTM
-146.80M
Debt / Equity
0.92
ROE
-292.19%
Net Debt
-140.73M
ROCE
-126.03%
Diluted EPS TTM
-1.12

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -204.21M -170.06M -88.05M -28.21M -64.26M
Net income -207.54M -169.21M -88.40M -27.20M -64.26M
Selling general administrative 56.96M 36.89M 21.90M 17.28M 16.33M
Gross profit 26.58M 0.04M 0.83M 42.12M 10.59M
Reconciled depreciation 0.93M 0.85M 1.01M 1.25M 1.26M
Ebit -204.69M -169.71M -87.69M -29.22M -66.91M
Ebitda -203.77M -168.86M -86.68M -27.97M -65.66M
Depreciation and amortization 0.93M 0.85M 1.01M 1.25M 1.26M
Non operating income net other - 0.07M 0.42M 2.23M 1.40M
Operating income -204.69M -169.71M -87.69M -29.22M -65.66M
Other operating expenses 230.35M 168.90M 88.94M 72.32M 76.25M
Interest expense 3.33M 1.27M 0.36M 0.23M 0.00M
Interest income 2.88M 0.07M 0.42M 2.23M 1.40M
Net interest income -0.45M -1.20M 0.07M 1.99M 1.40M
Income tax expense 3.33M -0.85M 0.36M -1.01M 1.40M
Total revenue 26.58M 0.04M 0.83M 42.12M 10.59M
Total operating expenses 230.35M 168.90M 88.94M 72.32M 76.25M
Cost of revenue - - - 55.04M 59.91M
Total other income expense net 0.48M -0.35M -0.36M 1.01M 1.40M
Net income from continuing ops -204.21M -170.06M -88.05M -28.21M -64.26M
Net income applicable to common shares -204.21M -170.06M -88.05M -28.21M -64.26M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 226.06M 334.34M 206.11M 273.40M 107.54M
Other current assets 4.97M 8.51M 10.95M 3.49M 1.54M
Total liab 189.16M 242.28M 84.37M 45.31M 29.22M
Total stockholder equity 36.90M 92.06M 121.74M 228.09M 78.32M
Deferred long term liab - - 0.46M - -
Other current liab 22.69M 44.17M 28.95M 16.24M 9.07M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -826.36M -654.69M -450.48M -280.42M -192.37M
Other liab - 117.04M 0.53M - -
Other assets - 0.66M 2.36M 13.09M 1.45M
Cash 174.56M 280.71M 177.95M 255.09M 62.35M
Total current liabilities 63.64M 91.53M 47.52M 30.00M 24.07M
Current deferred revenue 28.15M 30.61M 3.94M 3.99M 4.82M
Net debt -140.73M -244.41M -139.77M -238.52M -54.59M
Short term debt 5.48M 2.80M 2.30M 1.44M 2.89M
Short long term debt 2.08M - - - 0.67M
Short long term debt total 33.83M 36.30M 38.18M 16.57M 7.76M
Other stockholder equity 863.24M 746.89M 572.21M 508.50M 270.66M
Property plant equipment - 14.46M 14.86M 1.73M 4.76M
Total current assets 214.06M 319.22M 188.90M 258.58M 101.33M
Net tangible assets - 92.06M 155.55M 228.09M 78.32M
Short term investments 34.52M 151.83M - 0.00M 37.44M
Net receivables 0.00M 30.00M - - 0.00M
Long term debt 23.15M 24.93M 24.63M 4.98M 4.20M
Accounts payable 7.32M 13.95M 12.32M 8.34M 7.30M
Accumulated other comprehensive income 0.01M -0.15M - - 0.03M
Common stock total equity - - 0.01M 0.01M 0.01M
Retained earnings total equity - - -450.48M -280.42M -192.37M
Non currrent assets other 0.48M 0.66M 2.36M 2.15M 1.45M
Non current assets total 12.00M 15.12M 17.21M 14.82M 6.21M
Capital lease obligations 8.40M 11.37M 13.55M 11.60M 2.90M
Long term debt total - - 24.63M 4.98M 4.48M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -152.72M -0.65M 37.50M -26.69M 88.56M
Change to liabilities 144.66M 0.44M 8.22M -6.68M 12.81M
Total cashflows from investing activities -152.72M -0.65M 37.03M -27.29M 87.19M
Net borrowings -0.27M 18.34M -0.31M 4.96M 4.88M
Total cash from financing activities 153.02M 63.65M 230.41M 97.70M 1.06M
Change to operating activities 18.44M 9.64M 4.99M -1.50M 2.61M
Net income -204.21M -170.06M -88.05M -28.21M -64.26M
Change in cash -49.06M -76.99M 192.74M 2.67M 33.04M
Begin period cash flow 178.43M 255.41M 62.67M 60.01M 26.96M
End period cash flow 129.36M 178.43M 255.41M 62.67M 60.01M
Total cash from operating activities -49.36M -139.99M -74.70M -67.74M -55.22M
Issuance of capital stock 150.89M 43.09M 227.03M 92.16M 0.00M
Depreciation 0.93M 0.85M 1.01M 1.25M 1.26M
Other cashflows from investing activities - - - -26.69M 88.56M
Dividends paid - -0.64M -0.56M -0.49M -
Change to inventory - - - -1.50M 2.61M
Change to account receivables -30.00M -30.00M -30.00M 0.46M 0.33M
Sale purchase of stock 1.06M 0.64M 0.56M 0.49M 0.15M
Other cashflows from financing activities 1.33M 26.26M 3.70M 5.63M 0.92M
Change to netincome 20.82M 19.13M 7.32M 4.97M 3.90M
Capital expenditures 2.20M 0.65M 0.47M 0.60M 1.37M
Change receivables - - - 0.46M 0.33M
Cash flows other operating - -3.49M -3.12M -39.31M -8.96M
Cash and cash equivalents changes - -76.99M 192.74M 2.67M 33.04M
Change in working capital 133.10M 10.09M 5.11M -45.53M 4.18M
Stock based compensation 21.52M 18.41M 7.17M 4.87M 3.88M
Other non cash items -0.70M 0.72M 0.15M 0.10M 0.11M
Free cash flow -51.56M -140.64M -75.17M -68.35M -56.59M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

840 Memorial Drive, Cambridge, MA, United States, 02139

617 498 0020

https://www.mersana.com

123

Name Title Year Born
Ms. Anna Protopapas M.B.A. Pres, CEO & Director 1964
Mr. Brian C. DeSchuytner Sr. VP & CFO 1978
Dr. Timothy B. Lowinger Ph.D. Chief Science & Technology Officer 1964
Ms. Alejandra Veronica Carvajal J.D. SVP, Sec. & Chief Legal Officer 1974
Dr. Tushar Misra Ph.D. SVP & Chief Manufacturing Officer 1960
Mr. Mikhail Papisov Ph.D. Co-Founder NA
Mr. Ashish Mandelia VP, Controller & Principal Accounting Officer 1974
Mr. Jason Fredette Sr. VP of Investor Relations & Corp. Communications NA
Ms. Carla Poulson Chief People Officer NA
Mr. Chuck Miller Sr. VP of Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…